Indication
Recurrent Malignant Brain Neoplasm
2 clinical trials
3 products
1 drug
Clinical trial
Phase I Study of Cellular Immunotherapy Using Memory Enriched T Cells Lentivirally Transduced to Express an IL13Rα2-Targeting, Hinge-Optimized, 41BB-Costimulatory Chimeric Receptor and a Truncated CD19 for Children With Recurrent/Refractory Malignant Brain TumorsStatus: Recruiting, Estimated PCD: 2024-08-24
Drug
cyclophosphamideProduct
FludarabineClinical trial
Safety and Imaging of Post-Operative Low Dose Versus Standard Dose Dexamethasone in Patients With Primary or Metastatic Brain Tumors: a Randomized, Double-blinded Feasibility Study.Status: Active (not recruiting), Estimated PCD: 2025-09-03
Product
Dexamethasone